Maze Therapeutics (MAZE) Valuation Turns On Early Pipeline Data Following A Recent Share Price Bounce

Maze Therapeutics (MAZE) drew investor attention after recent trading left the stock at US$27.18, with performance reflecting a small gain over the past month and a decline over the past 3 months.

For context, Maze Therapeutics has logged a 3.7% 7‑day share price return and a 2.45% 30‑day share price return. However, the 90‑day share price return is down 13.05% and the year to date share price return is down 31.66%, while the 1‑year total shareholder return of 2.57% points to modest overall gains. This suggests that short term momentum has been fading even as long term holders have seen a small positive result.

Scan beyond Maze Therapeutics and compare how other biopharma players with similar momentum profiles line up in our curated 19 high quality undiscovered gems.

Bulls point to Maze Therapeutics’ pipeline and recent uptick, while bears focus on ongoing losses and a sharp year to date decline. Which story does the current valuation lean toward as you weigh the trade off?

Most Popular Narrative: 56.5% Undervalued

Analysts following Maze Therapeutics see a fair value of about $62.55 per share, which sits well above the recent $27.18 close. That narrative leans heavily on the pipeline turning clinical signals into future economics.

Phase I data for MZE782 that showed very large increases in urinary phenylalanine excretion and a dose dependent eGFR dip of similar magnitude to SGLT2 inhibitors supports the potential for a single small molecule to address both PKU and chronic kidney disease. This could be relevant for long term revenue growth and operating leverage if development is successful.

See why 1 investors see Maze Therapeutics as 57% undervalued.

Result: Fair Value of $62.55 (UNDERVALUED)

Still, the story around Maze Therapeutics can change quickly if trial data disappoints or if further equity raises dilute any potential upside implied by today’s forecasts.

Find out about the key risks to this Maze Therapeutics narrative.

Next Steps

Mixed sentiment around Maze Therapeutics is clear, so move quickly, review the underlying data, and make your own call using the 1 key reward and 4 important warning signs.

Looking for more investment ideas beyond Maze Therapeutics?

Do not stop with Maze Therapeutics. Broaden your watchlist with fresh angles on quality, risk, and income potential using the Simply Wall Street Screener.

• Target potential mispricings by scanning a curated set of companies that combine strong fundamentals with appealing valuations through the 31 high quality undervalued stocks.
• Protect your downside by focusing on businesses that carry resilient financial profiles using the 31 resilient stocks with low risk scores.
• Build a watchlist of firms with healthier balance sheets and solid underlying metrics through the list of solid balance sheet and fundamentals (25 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com